

Toledo, Jb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9272403/publications.pdf>

Version: 2024-02-01

94
papers

13,625
citations

26610

56
h-index

43868

91
g-index

98
all docs

98
docs citations

98
times ranked

17055
citing authors

#	ARTICLE	IF	CITATIONS
1	ADCoC: Adaptive Distribution Modeling Based Collaborative Clustering for Disentangling Disease Heterogeneity from Neuroimaging Data. IEEE Transactions on Emerging Topics in Computational Intelligence, 2023, 7, 308-318.	3.4	1
2	A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease. Parkinsonism and Related Disorders, 2022, 97, 57-62.	1.1	9
3	Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	9
4	The Brain Chart of Aging: Machineâ€learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. Alzheimer's and Dementia, 2021, 17, 89-102.	0.4	92
5	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5
6	Disentangling disease heterogeneity from neuroimaging data via adaptive distribution modelingâ€based collaborative clustering. Alzheimer's and Dementia, 2021, 17, .	0.4	0
7	Inflammatory markers and imaging patterns of advanced brain aging in the general population. Brain Imaging and Behavior, 2020, 14, 1108-1117.	1.1	26
8	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. journal of applied laboratory medicine, The, 2020, 5, 183-193.	0.6	10
9	Dataâ€driven approach reveals heterogeneity and regionâ€specific association of white matter hyperintensities with the APOE genotype. Alzheimer's and Dementia, 2020, 16, e037342.	0.4	0
10	Sex and APOE Î¼4 genotype modify the Alzheimerâ€™s disease serum metabolome. Nature Communications, 2020, 11, 1148.	5.8	115
11	APOE Effect on Amyloid-Î² PET Spatial Distribution, Deposition Rate, and Cut-Points. Journal of Alzheimer's Disease, 2019, 69, 783-793.	1.2	15
12	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys AÎ²(1â€42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
13	Elevated CSF GAPâ€43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
14	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.4	396
15	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
16	Dysregulation of the epigenetic landscape of normal aging in Alzheimerâ€™s disease. Nature Neuroscience, 2018, 21, 497-505.	7.1	236
17	Regional tractâ€specific white matter hyperintensities are associated withÂpatterns of agingâ€related brain atrophy via vascular risk factors, butÂalso independently. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 278-284.	1.2	35
18	A Longitudinal Study of Total and Phosphorylated Î±-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1541-1553.	1.2	29

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	3.9	114
20	Cerebrospinal fluid β -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
21	Characterizing the human hippocampus in aging and Alzheimer's disease using a computational atlas derived from ex vivo MRI and histology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4252-4257.	3.3	136
22	P168: ASSOCIATION OF OLFACTORY SCORE WITH LONGITUDINAL COGNITION AND NEUROPATHOLOGICAL DIAGNOSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P384.	0.4	0
23	White matter lesions. <i>Neurology</i> , 2018, 91, e964-e975.	1.5	92
24	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. <i>PLoS Medicine</i> , 2018, 15, e1002482.	3.9	336
25	Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. <i>Brain</i> , 2017, 140, aww319.	3.7	114
26	Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. <i>Alzheimer's and Dementia</i> , 2017, 13, 770-777.	0.4	20
27	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
28	Multisite Assessment of Aging-Related Tau Astroglial Pathology (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	0.9	38
29	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	179
30	Patterns of coordinated cortical remodeling during adolescence and their associations with functional specialization and evolutionary expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3527-3532.	3.3	130
31	Metabolic network failures in Alzheimer's disease: A biochemical roadmap. <i>Alzheimer's and Dementia</i> , 2017, 13, 965-984.	0.4	362
32	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. <i>Scientific Data</i> , 2017, 4, 170140.	2.4	49
33	TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. <i>Current Biology</i> , 2017, 27, 3579-3590.e6.	1.8	63
34	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 89.	3.0	129
35	Impaired functional default mode network in patients with mild neurological Wilson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 46-51.	1.1	14
36	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. <i>Neurology</i> , 2016, 87, 1227-1234.	1.5	25

#	ARTICLE	IF	CITATIONS
37	A framework for informing segmentation of in vivo MRI with information derived from ex vivo imaging: Application in the medial temporal lobe. , 2016, 2016, 6014-6017.		2
38	Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort. American Journal of Neuroradiology, 2016, 37, 1636-1642.	1.2	36
39	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380
40	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathologica, 2016, 131, 935-949.	3.9	190
41	Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization. Journal of Neurosurgery, 2016, 125, 1068-1079.	0.9	41
42	White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain, 2016, 139, 1164-1179.	3.7	314
43	Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 45-51.	1.1	97
44	Pathological β -synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathologica, 2016, 131, 393-409.	3.9	123
45	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. Journal of Alzheimer's Disease, 2015, 48, 433-441.	1.2	41
46	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	1.2	67
47	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	3.9	65
48	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.4	79
49	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
50	Memory, executive, and multidomain subtle cognitive impairment. Neurology, 2015, 85, 144-153.	1.5	42
51	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β -Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
52	Role of brain infarcts in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2861-2868.	1.5	14
53	Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	1.2	35
54	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology, 2014, 83, 502-509.	1.5	26

#	ARTICLE	IF	CITATIONS
55	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. <i>Acta Neuropathologica Communications</i> , 2014, 2, 26.	2.4	77
56	CSF Apo-E levels associate with cognitive decline and MRI changes. <i>Acta Neuropathologica</i> , 2014, 127, 621-632.	3.9	60
57	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). <i>Acta Neuropathologica</i> , 2014, 127, 423-439.	3.9	237
58	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. <i>Acta Neuropathologica</i> , 2014, 128, 679-689.	3.9	158
59	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. <i>Acta Neuropathologica</i> , 2014, 128, 423-437.	3.9	203
60	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.4	167
61	High beta activity in the subthalamic nucleus and freezing of gait in Parkinson's disease. <i>Neurobiology of Disease</i> , 2014, 64, 60-65.	2.1	113
62	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2014, 35, 1473-1482.	1.5	43
63	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. <i>NeuroImage: Clinical</i> , 2014, 4, 164-173.	1.4	112
64	A comparison of A β ² amyloid pathology staging systems and correlation with clinical diagnosis. <i>Acta Neuropathologica</i> , 2014, 128, 543-550.	3.9	26
65	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid- β ²⁴² in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 441-451.	1.2	94
66	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 36.	3.0	26
67	Lifestyle factors modify obesity risk linked to PPARG2 and FTO variants in an elderly population: a cross-sectional analysis in the SUN Project. <i>Genes and Nutrition</i> , 2013, 8, 61-67.	1.2	27
68	CSF β -synuclein improves diagnostic and prognostic performance of CSF tau and A β ² in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 683-697.	3.9	90
69	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. <i>Journal of Comparative Neurology</i> , 2013, 521, 4339-4355.	0.9	47
70	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. <i>Brain</i> , 2013, 136, 2697-2706.	3.7	609
71	Longitudinal change in CSF Tau and A β ² biomarkers for up to 48 months in ADNI. <i>Acta Neuropathologica</i> , 2013, 126, 659-670.	3.9	160
72	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. <i>Acta Neuropathologica Communications</i> , 2013, 1, 65.	2.4	138

#	ARTICLE	IF	CITATIONS
73	Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 8.	3.0	113
74	Can MRI screen for CSF biomarkers in neurodegenerative disease?. <i>Neurology</i> , 2013, 80, 132-138.	1.5	21
75	Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- β 1-42 and τ , Proteins as Alzheimer Disease Biomarkers. <i>Clinical Chemistry</i> , 2013, 59, 903-916.	1.5	139
76	Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2013, 74, 20-38.	2.8	820
77	Cognitive decline and reduced survival in <i>C9orf72</i> expansion frontotemporal degeneration and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 163-169.	0.9	141
78	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 949-955.	0.9	82
79	Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI. <i>PLoS ONE</i> , 2013, 8, e55531.	1.1	41
80	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. <i>PLoS ONE</i> , 2013, 8, e70269.	1.1	50
81	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. <i>Brain</i> , 2012, 135, 3749-3756.	3.7	228
82	Comparison of Cerebrospinal Fluid Levels of Tau and $A\beta$ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms. <i>Archives of Neurology</i> , 2012, 69, 1018-25.	4.9	100
83	Neuropathologic substrates of Parkinson disease dementia. <i>Annals of Neurology</i> , 2012, 72, 587-598.	2.8	401
84	Cardiovascular risk factors, cortisol, and amyloid- β 1-42 deposition in Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 483-489.	0.4	113
85	Improved protocol for measurement of plasma $A\beta$ -amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. , 2012, 8, 250-260.		56
86	Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2012, 7, e39216.	1.1	210
87	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. <i>Acta Neuropathologica</i> , 2012, 124, 23-35.	3.9	161
88	Pattern of ubiquilin pathology in ALS and FTLN indicates presence of C9ORF72 hexanucleotide expansion. <i>Acta Neuropathologica</i> , 2012, 123, 825-839.	3.9	164
89	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2012, 123, 395-407.	3.9	104
90	Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. <i>Brain</i> , 2011, 134, 36-49.	3.7	187

#	ARTICLE	IF	CITATIONS
91	Factors affecting A β plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011, 122, 401-13.	3.9	151
92	Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. <i>Movement Disorders</i> , 2009, 24, 1437-1444.	2.2	82
93	RETINAL NERVE FIBER LAYER IS ASSOCIATED WITH BRAIN ATROPHY IN MULTIPLE SCLEROSIS. <i>Neurology</i> , 2008, 71, 1747-1748.	1.5	11
94	Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 699-704.	1.8	92